Abstract: Systems and methods are provided to provide guidance to a user regarding management of a physiologic condition such as diabetes. The determination may be based upon a patient glucose concentration level. The glucose concentration level may be provided to a stored model to determine a state. The guidance may be determined based at least in part on the determined state.

Abstract: Nozzles, nozzle assemblies, and blaster assemblies featuring interchangeable nozzles having externally powered electrical components or accessories. A nozzle assembly may include a body. The body may have a projectile opening defined therethrough. The nozzle assembly may further include an electrical component that is attachable to the body. The nozzle assembly may further include an electrical connection member coupled to the body and the electrical component. The electrical connection member may be configured to electrically connect the electrical component to the blaster.

Abstract: A delivery system for an occlusive implant includes a delivery sheath assembly and a hub assembly. The delivery sheath assembly includes a delivery sheath defining a delivery lumen adapted to accommodate an occlusive implant releasably secured to a core wire. A proximal fitting is secured to the delivery sheath. The hub assembly includes a hub body, a distal hub secured relative to the hub body and adapted to engage the proximal fitting of the delivery sheath assembly, a proximal hub secured to the hub body, and a side port coupled to hub body and adapted for flushing an interior of the delivery system. The delivery system includes one or more features that are adapted to limit relative rotation between the delivery sheath assembly and the hub assembly when the core wire is rotationally locked to the proximal hub.

Abstract: Delivery devices for an occlusive implant and method for making and using delivery devices are disclosed. An example delivery device may include a delivery sheath having a sheath body and a distal tip region. A tip reinforcing member may be coupled to the distal tip region. The tip reinforcing member may define a plurality of distal arm segments. The distal arm segments are configured to shift between a first configuration and an expanded configuration. A core member may be slidably disposed within the delivery sheath. An occlusive implant may be releasably coupled to the core member.

Abstract: The invention relates to a particular enantiomer of a substituted heterocycle fused gamma-carboline, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving the 5-HT2A receptor, and pathways involving the dopamine D1 and D2 receptor signaling system.

Abstract: The invention relates to a particular substituted heterocycle fused gamma-carboline, in free, or pharmaceutically acceptable salt, and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving the 5-HT2A receptor, the serotonin transporter (SERT), and/or pathways involving the dopamine D1 and D2 receptor signaling system.

Abstract: A multi-layer coating system includes: a first coating layer formed from a first coating composition including: a film forming resin; and a fluorescent and/or phosphorescent pigment that: (1) emits radiation at an emission wavelength in the range of from 400-1200 nanometers when excited by ultraviolet and/or visible radiation corresponding to an excitation wavelength of the fluorescent and/or phosphorescent pigment; and/or (2) emits radiation at an emission wavelength in the range of from 600-2500 nanometers when excited by visible and/or near infrared radiation corresponding to an excitation wavelength of the fluorescent and/or phosphorescent pigment; and a second coating layer disposed over at least a portion of the first coating layer, which is formed from a second coating composition including: a film forming resin; and a pigment that blocks radiation corresponding to the excitation and/or emission wavelength of the fluorescent and/or phosphorescent pigment in the first coating layer.

Abstract: The disclosure provides new transdermal pharmaceutical compositions comprising 1-(4-fluoro-phenyl)-4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3?,4?:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one or 1-(4-fluoro-phenyl)-4-((6bR,10aS)-2,2-d2-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3?,4?:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one or comprising—(4-fluoro-phenyl)-4-((6bR,10aS)-1,1,2,2-d4-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3?,4?:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one, in free base, co-crystal or salt form, together with methods of making and using them.

Abstract: The present disclosure includes a split ring wire bundle seal sleeve and an assembly technology for pressurized electrical feedthroughs. A kit of parts is also described.

Abstract: The invention relates to particular prodrugs of substituted heterocycle fused gamma-carbolines, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving the 5-HT2A receptor, the serotonin transporter (SERT), pathways involving the dopamine D1 and D2 receptor signaling system, and/or the ?-opioid receptor.

Abstract: The disclosure provides new transdermal pharmaceutical compositions comprising 1-(4-fluoro-phenyl)-4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3?,4?:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one or 1-(4-fluoro-phenyl)-4-((6bR,10aS)-2,2-d2-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3?,4?:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one or comprising -(4-fluoro-phenyl)-4-((6bR,10aS)-1,1,2,2-d4-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3?,4?:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one, in free base, co-crystal or salt form, together with methods of making and using them.

Abstract: The disclosure provides methods for the treatment of Bipolar II Disorder, comprising administering to a patient in need thereof, a therapeutically effective amount of lumateperone, in free or pharmaceutically acceptable salt form, optionally in deuterated form.

Abstract: The present disclosure relates to pharmaceutical capsules comprising lumateperone, in free, or pharmaceutically acceptable salt form, optionally in combination with one or more additional therapeutic agents, processes for manufacture thereof and methods of use in the treatment or prophylaxis of disease.

Abstract: The disclosure provides methods for the acute treatment of depression and/or anxiety, for the enhancement of mTOR (e.g., mTORC1) signaling, and for the reduction of neuroinflammation, comprising administering to a patient in need thereof, a therapeutically effective amount of a 5-HT2A/mu-opioid receptor or 5-HT2A/D1 and/or D2/mu-opioid receptor ligand.

Abstract: The disclosure provides methods for the treatment of Bipolar II Disorder, comprising administering to a patient in need thereof, a therapeutically effective amount of lumateperone, in free or pharmaceutically acceptable salt form, optionally in deuterated form.

Abstract: According to an aspect of the present invention disclosed herein, there is provided buckle, comprising: a male component and a female component, wherein: the male component comprises: a slot for a strap at an end of the male component opposite the side where the male component is configured to insert into the female component; an inclined insert; and one or more mating slots in the inclined insert; and the female component comprises: a top wall, a bottom wall, and sidewalls forming a receiving portion; a plurality of teeth; a slot for a strap; and a chord, wherein the chord is configured that when pulled the teeth disengage just enough for the male component to be released.

Abstract: The present disclosure relates to pharmaceutical capsules comprising lumateperone, in free, or pharmaceutically acceptable salt form, optionally in combination with one or more additional therapeutic agents, processes for manufacture thereof and methods of use in the treatment or prophylaxis of disease.

Abstract: A reinforcing element for reinforcing a structural element in a motor vehicle, the reinforcing element including: a carrier; an expandable material, the expandable material being arranged at least partially on the carrier; at least two fixation elements that are connected with the carrier, the fixation elements each including a circular metallic tab with an essentially flat central section adapted for welding, and the fixation elements being arranged in such a way that the reinforcing element is fixable to the structural element with a weld connection between the tabs and the structural element; wherein the circular metallic tabs are enclosed by material of the carrier; and wherein the fixation elements are arranged in a peripheral area of the carrier.

Abstract: A variety of medical procedures utilize two or more medical device components, including medical device components where a first medical device component is advanced within a second medical component. An example would be an elongate dilator used in combination with a guide catheter. The guide catheter and the elongate dilator may be adapted to provide a rotational lock mechanism that allows the guide catheter and the elongate dilator to lock together such that rotating one of the components causes rotation of both components. In some instances, the guide catheter and the elongate dilator may cooperate to also provide a relative axial lock between the two components.

Abstract: The disclosure provides methods for the acute treatment of depression and/or anxiety, for the enhancement of mTOR (e.g., mTORC1) signaling, and for the reduction of neuroinflammation, comprising administering to a patient in need thereof, a therapeutically effective amount of a 5-HT2A or 5-HT2A/D2 receptor ligand, e.g. lumateperone.